$275.83-5.13 (-1.83%)
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States.
The Cigna Group in the Healthcare sector is trading at $275.83 with a market capitalization of $74.7B. Wall Street consensus targets $341.42 (24 analysts), implying a +23.8% move over the next 12 months. The stock is currently 13% below its 52-week high of $315.47, remaining 0.2% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $71.40B↑ | $68.29B↓ | $72.13B↑ | $69.52B↑ | $66.94B |
| Gross Profit | $6.26B | $6.27B↑ | $6.08B↓ | $6.14B↑ | $5.92B |
| Operating Income | $2.40B↑ | $2.16B↑ | $2.01B↓ | $2.35B↑ | $2.07B |
| Net Income | $1.66B↑ | $1.65B↑ | $1.23B↓ | $1.87B↑ | $1.53B |
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includ...

As employers brace for a fresh round of rising healthcare costs that outpace inflation, the stakes are getting higher for companies to contain spending on treatments such as popular GLP-1 medications for weight loss.

UnitedHealth (UNH) stock has gained about 41% since early March, and at roughly $400 a share the market has already paid for a recovery. The easy reading is that the turnaround is finished. It is not. One half got better over those six months, the other got worse, and the price reflects the good half.

The market has crowned this healthcare giant the winner of its group, but a look at the underlying business raises the question of whether the celebration started too soon.

Cigna Healthcare recently introduced an industry-first connected benefits experience that links medical and supplemental health coverage to simplify access to cash benefits for unexpected health events, with Medical with Smart Coverage slated to begin offering supplemental cash of up to US$7,000 per covered event from January 2027 for eligible mid-sized employer plans. This move directly addresses widespread gaps in Americans’ financial readiness for medical shocks and the underuse of...

CI has underperformed the broader market over the past year, despite analysts remaining moderately bullish on its future prospects.
Academic risk and quality models computed from CI's own filings and price history, not from analyst opinion.
Strong on 7 of 9 fundamental-health tests covering profitability, leverage and operating efficiency.
Altman Z in the 1.81 to 2.99 grey zone, the band where the model gives no clear bankruptcy verdict.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, above the current 29.6% reading.
Fama-French 5-factor market beta. The five factors explain 9% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-09-08.